ReviewTrends in immunology2017
Expanding the B Cell-Centric View of Systemic Lupus Erythematosus.
Review in Trends in immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Pooled it
- Telitacicept demonstrates high probability of efficacy in myasthenia gravis: a Bayesian real-world study.Frontiers in neurology · 2025Article
- ELF1 serves as a potential biomarker for the disease activity and renal involvement in systemic lupus erythematosus.Scientific reports · 2024Article
- Severe lupus nephritis in a young adult with PTEN hamartoma tumour syndrome.BMJ case reports · 2024Article
- A new perspective on therapies involving B-cell depletion in autoimmune diseases.Molecular biology reports · 2024Article
- Observational
- Identifying lupus Patient Subsets Through Immune Cell Deconvolution of Gene Expression Data in Two Atacicept Phase II Studies.ACR open rheumatology · 2023Article
- Aberrant expansion of follicular helper T cell subsets in patients with systemic lupus erythematosus.Frontiers in immunology · 2022Article
- Impact of the COVID-19 pandemic in patients with systemic lupus erythematosus throughout one year.Clinical immunology (Orlando, Fla.) · 2021Article
- Article
- Systemic Lupus Erythematosus and Periodontal Disease: A Complex Clinical and Biological Interplay.Journal of clinical medicine · 2021Review
- Basophils as a potential marker of lupus nephritis by flow cytometry.Future science OA · 2021Article
- CRAC Channel Controls the Differentiation of Pathogenic B Cells in Lupus Nephritis.Frontiers in immunology · 2021Article
- Aberrant Non-Coding RNA Expression in Patients with Systemic Lupus Erythematosus: Consequences for Immune Dysfunctions and Tissue Damage.Biomolecules · 2020Review
- COVID-19 in systemic lupus erythematosus: Data from a survey on 417 patients.Seminars in arthritis and rheumatism · 2020Article
- Is hydroxychloroquine beneficial for COVID-19 patients?Cell death & disease · 2020Review
- B Cell Tetherin: A Flow Cytometric Cell-Specific Assay for Response to Type I Interferon Predicts Clinical Features and Flares in Systemic Lupus Erythematosus.Arthritis & rheumatology (Hoboken, N.J.) · 2020Article
- Molecular and Cellular Bases of Immunosenescence, Inflammation, and Cardiovascular Complications Mimicking "Inflammaging" in Patients with Systemic Lupus Erythematosus.International journal of molecular sciences · 2019Review
- Anti-CD22 epratuzumab for systemic lupus erythematosus: A systematic review and meta-analysis of randomized controlled trials.Experimental and therapeutic medicine · 2019Article
- Strong Selection of a Few Dominant CD8 Clones in a TLR7-Dependent Autoimmune Mouse Model.ImmunoHorizons · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Systemic lupus erythematosus (SLE) is an autoimmune disorder characterized by a breakdown of self-tolerance in B cells and the production of antibodies against nuclear self-antigens. Increasing evidence supports the notion that additional cellular contributors beyond B cells are important for lupus pathogenesis. In this review we consider recent advances regarding both the pathogenic and the regulatory role of lymphocytes in SLE beyond the production of IgG autoantibodies. We also discuss various inflammatory effector cell types involved in cytokine production, removal of self-antigens, and responses to autoreactive IgE antibodies. We aim to integrate these ideas to expand the current understanding of the cellular components that contribute to disease progression and ultimately help in the design of novel, targeted therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.